Granule and method for making thereof. RU patent 2456980.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics. A pharmaceutical granule is spherical or spheroidal and has volume density 0.6-1.3 g/ml and disintegration 0.5-5 minutes. Active pharmaceutical ingredients are preparations of Traditional Chinese Medicine, herbal preparations or their extracts with a nucleus made of an extract of Traditional Chinese Medicine or herbal preparations, and a pharmaceutically acceptable carrier. The content of the pharmaceutically acceptable carrier with respect to total granule weight makes 10-60 wt %. The granule diameter can be equal to 700-1500 mcm. The granule nucleus diameter can be equal to 200-750 mcm. The granule can be also coated with a layer of 2-5 wt % with respect of total granule weight. A method for making the granules consists in introducing initial granules into a layer of a fluidised material as an excipient; the active pharmaceutical ingredients are prepared in the form of a suspension or a solution of the viscosity controlled within 6.0-9.8 MPa·s with using a viscosity-control agent; then they are sprayed over a surface of the initial granule for making a finished granule.

EFFECT: granules possess fast disintegration, contain a small amount of the carrier and contain a low single dose.

12 cl, 5 ex

IPC classes for russian patent Granule and method for making thereof. RU patent 2456980. (RU 2456980):

A61P9/10 - for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

A61P3/10 - for hyperglycaemia, e.g. antidiabetics

A61P31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P25 - Drugs for disorders of the nervous system

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K9/16 - Agglomerates; Granulates; Microbeadlets

A61K47/38 - Cellulose; Derivatives thereof

A61K47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

A61K47/04 - Non-metals; Compounds thereof

A61K36 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

Another patents in same IPC classes:

New benzyl-substituted derivatives 1, 4-benzothiepin-1, 1-dioxide / 2456282
Invention refers to compounds of formula I, as well as to their physiologically acceptable salts wherein: X means NH; R1 means (C1-C6)-alkyl; R2 means OH; R2' means H; R5' means (C1-C6)-alkylene-O-S(O)2-R6; R3, R3', R4, R4' and R5 independently mean H, OH, (C1-C6)-alkylene-O-S(O)p-R6, O-(CH2)m-phenyl; at least one of the radicals R3, R3', R4, R4' and R5 has the value -O-(CH2)m-phenyl; R6 means OH; m=1; p=2.

Benzimidazole derivatives, based pharmaceutical composition and methods of using them / 2456276
Present invention refers to new benzimidazole derivatives of general formula (I) or to its pharmacologically acceptable salts wherein R1 represents a C6-aryl group which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), or a heterocyclic group which represents pyridyl, dihydrobenzofuranyl, 1,3-benzodioxolyl, tetrahydropyranyl, tetrahydrofuranyl which can be substituted by 1-3 groups optionally specified in a group of substitutes (a), R2 represents a C1-C6 alkyl group, R3 represents a C6-aryl group which can be substituted by 1-2 groups optionally specified in a group of substitutes (a), Q represents a group represented by formula =CH-, or a nitrogen atom and a group of substitutes (a) represents a group consisting of a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a carboxyl group, a C2-C7 alkylcarbonyl group, a C2-C7 alkoxycarbonyl group, a C1-C6 alkoxy group, a C1-C6 halogenated alkoxy group, an amino group, a 4-morpholinyl group and a di-C1-C6 alkyl)amino group. Also, the invention refers to a pharmaceutical composition based on a compound of formula (I), to a PPARγ activator/modulator based on the compound of formula (I), to using the compound of formula (I), to a method of reducing blood glucose, to a method of activating PPARγ, a method of treating and/or preventing said pathological conditions.

Cardioprotection technique / 2456024
Invention refers to medicine, namely cardiology, and may be used for myocardium protection against ischemic and reperfusion injures. That is ensured by the target drug delivery to the ischemic-reperfused myocardium. Aminated silica nanoparticles of the diameter of 10 nm wherein a spacer is grafter are used as a drug carrier. A drug substance is immobilised on a functional group of the spacer by one of the following methods: covalent binding, coordination ion interaction, immobilisation by adsorption.

Method of estimating efficacy of vascular therapy by endothelial dysfunction intensity / 2455641
Before the drug prescription and during the therapeutic progression, patient's peripheral venous blood is sampled, ultracentrifuged to recover endotheliocytes to be incubated with PTS-marked annexin-V. It is followed by endotheliocyte count with using an immersion microscope in 10 vision fields and the prevailing content of annexin-V negative endotheliocytes prevailing over annexin-V positive endotheliocytes enables stating the low involvement of vascular endothelium in the pathological process or the efficacy of vascular therapy; annexin-V positive endotheliocytes prevailing over annexin-V negative endotheliocytes makes it possible to state the high involvement of the endothelium in the pathological process or the inefficacy of vascular therapy: normal average number of circulating endotheliocytes 1-3, annexin-V positive - 0; in degree 1 endothelial dysfunction, the number of circulating endotheliocytes 4-6 wherein 1-3 - annexin-V positive; in degree 2 endothelial dysfunction, the number of circulating endotheliocytes 7-12 wherein 4-6 annexin-V positive; in degree 3 endothelial dysfunction, the number of circulating endotheliocytes 13-18 wherein annexin-V positive 7-10; in degree 4 endothelial dysfunction, the number of circulating endotheliocytes 19-25, annexin-V positive 12-24, in critical endothelial dysfunction with a high risk of cardiovascular complications, the number of circulating endotheliocytes more than 25, all of them are annexin-V positive.

Method of pharmacological correction of extremity ischemia by mixed solutions of homoeopathic dilutions / 2455025
Invention refers to medicine. The method of pharmacological correction of extremity ischemia by mixed solutions of homoeopathic dilutions in an experimental laboratory animal suffering experimental extremity ischemia, consists in the intragastric introduction of the mixed solutions of homoeopathic dilutions of monoclonal VEGF -C12, C30, C200 antibodies 4.5 ml/kg (9 ml/kg/day) to the laboratory animals twice a day for 28 days following ischemia simulation.

Vascular ageing inhibitor and anti-ageing composition / 2455022
Group of inventions refers to medicine, and concerns a vascular ageing inhibitor which contains as a basic ingredient collagen of low molecular weight approximately 3000 Da of fish skin prepared by enzymatic decomposition with using anacanthe or flatfish skin. The anti-ageing compositions contain the vascular ageing inhibitor in the granulated form.

Method for preventing and treating atherosclerosis / 2455016
Invention refers to medicine, namely therapy, and concerns preventing and treating atherosclerosis. That is ensured by prescribing tablets or capsules the active ingredients of which contain black elderberry, marigold blossom and violet herb in certain proportions. There are prescribed two tablets or two capsules twice a day every 12 hours with unlimited length of the therapeutic course.

Immunotherapeutic treatment / 2454428
Present invention refers to immunology. What is presented is using immunotherapy for the purpose of inducing atherosclerotic plaque regression, involving introducing oxidised low-density lipoproteins (LDLP) containing the epitope ApoB-100, or antibodies thereto. There are also contemplated a method of inducing atherosclerotic plaque regression, a method of treating, using oxidised oxidised LDLP epitopes and antibodies thereto for preparing a drug, a pharmaceutical composition, a set, and also methods of identifying antibodies and agents which induce atherosclerotic plaque regression.

2-ethyl-6-methyl-3-hydroxypyridine and nicotinic acid salt, having hypoglycemic, hypolipidemic and neuroprotective activity and synthesis method thereof / 2454406
Invention relates to a salt of 2-ethyl-6-methyl-3-hydroxypyridine with nicotinic acid, a method of producing said salt, as well as a method of correcting metabolic disorders in case of sugar diabetes with diabetes with exogenous hypercholesteremia and morphofunctional disorders and brain during acute ischemia.

Method for l-norvaline correction of hyperhomocystein induced nitrogen oxide deficiency in experiment / 2453001
Studying of mechanisms of correction and prevention of developing hyperhomocytein-induced nitrogen oxide deficiency in a body in experiment is ensured simulating nitrogen oxide deficiency in a laboratory animal by the intragastric introduction of methionine 3 g/kg daily within 7 days. A degree of developing deficiency is evaluated by the relation of endothelium-independent and endothelium-dependent vasodilation (EDV and EIDV). Nitrogen oxide deficiency is corrected by the intragastric introduction of L-norvaline 10 mg/kg 1 hour after the introduction of methionine for 7 days as well.

Incretin secretagogues, methods for preparing and applying them / 2456287
Invention refers to new compounds of general formula 1, or their pharmaceutically acceptable salts showing the properties of incretin secretagogues, preferentially the properties of a bile acid receptor TGR5 agonist. The compounds are applicable for treating metabolic diseases associated with glucose metabolism, such as diabetes, obesity, metabolic syndrome, etc. In formula 1 R1, R2 and R3 independently represent a cyclic system substitute specified in: hydrogen, C1-C3alkyl, halogen, a trifluoromethyl group, C1-C3alkoxy, a cyano group, a trifluoromethoxy group; an amino group substituted by C1-C3alkyl; or two radicals R3, found at carbon neighbours in a benzene ring, together with the benzene ring bound therewith form 3,4-methylene dioxyphenyl; R4 represents hydrogen, C1-C5alkyl, a carboxyl group, C1-C3alkoxycarbonyl or an amide group CONHR5; R5 is an optionally substituted by C1-C3alkyl, C5-C6cycloalkyl optionally substituted by phenyl, benzyl, pyridyl; X and Y represent two hydrogen atoms or an oxygen atom, provided Y=O, then X=2H, provided Y=2H, then X=O or X=Y=2H; the sign (N) shows the possibility of bioisosteric substitution of the benzene ring by the pyridine, pyrimidine, pyridazine, triazine or pyrazine ones.

Substituted 4-imidazoles, method for preparing and using them / 2456281
Present invention refers to new imidazole derivatives of formula I wherein R1 represents a hydrogen atom or C1-7alkyl; R2 represents C1-7alkyl; R3 represents C1-7alkyl, C1-7alkoxy, phenyloxy, benzyloxy, a halogen atom or C1-7alkyl substituted by a halogen atom; R4 represents a hydrogen atom or C1-7alkyl; X represents -CH2-, -CHR2 - or -O; Y represents -CH2-, -CH2CH2- or a bond; provided X represents -O-, Y represents -CH2-; Z represents -CH2- or -CHR2-; provided R2 is found twice, simultaneously for X and Z which are CHR2 , then R2 can be identical alkyls or different; n has the value 0, 1 or 2; provided n has the value 2, R3 can be identical or different; and its pharmaceutically acceptable acid addition salts, except for the following compounds: 1-(1H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinoline and 1-(3H-imidazol-4-ylmethyl)-2,3-dihydro-1H-indole. Also, the invention refers to a method for preparing the compounds of formula I, to a drug based on the compound of formula I and applying the compound of formula I in preparing the drug.

N-(2-benzothiazolyl)amide of 3-bromo-2,4-dioxo-4-(4-methoxy phenyl)butanoic acid, having hypoglycemic activity / 2455293
Invention relates to N-(2-benzothiazolyl)amide of 3-bromo-2,4-dioxo-4-(4-methoxy phenyl)butanoic acid of formula 1.

Nitrogen containing heterocyclic derivative showing type i 11β -hydroxysteroiddehydrogenase inhibitory activity / 2455285
Invention refers to a compound of formula (II)

Indole derivative / 2454415
Object of the present invention is preparing a glucokinase activator effective as a pharmaceutical agent, such as an agent for preventing or treating diabetes, obesity and similar. The present invention presents the glucokinase activator containing a compound presented by formula :

New piperazine amide derivatives / 2454412
Invention refers to new piperazine amide derivatives of formula wherein X represents N or CH; Y represents N or CH; R1 represents lower alkyl, phenyl, phenyl-lower alkyl wherein phenyl can be optionally substituted by 1-2 substitutes independently specified in a group consisting of halogen, lower alkyl; R2 represents lower alkyl, phenyl, naphthyl or heteroaryl specified in dimethylisoxazolyl, quinolinyl, thiophenyl or pyridinyl wherein phenyl or heteroaryl are optionally substituted by 1 substitute optionally specified in a group consisting of halogen, lower alkoxy group, fluor-lower alkyl, lower alkoxy-carbonyl and phenyl; R3 represents phenyl, pyridinyl or pyrazinyl wherein phenyl, pyridinyl or pyrazinyl are substituted by 1-2 substituted optionally specified in a group consisting of halogen, lower alkyl and fluor-lower alkyl; R4, R5, R6, R7, R8, R9, R10 and R11 independently represent hydrogen, as well as to their physiologically acceptable salts. These compounds are bound with LXR alpha and LXR beta, and are applicable as therapeutic agents for treatment and/or prevention of high lipid levels, high cholesterol levels, low HDL cholesterol, high LDL cholesterol, atherosclerotic diseases, diabetes, non insulin dependent diabetes mellitus, metabolic syndrome, dislipidemia, sepsis, inflammatory diseases, infectious diseases, skin diseases, colitis, pancreatitis, cholestasis, liver fibrosis, psoriasis, Alzheimer's disease, etc.

Novel pyridone derivatives, having mch antagonist activity, and medicinal agent containing said compounds / 2453543
Invention relates to compounds of general formula (I),

Method for producing macrocyclic compounds / 2456296
Present patent claim discloses sulphonyl-substituted compounds of formula QUIN which are used for the purpose of a method for producing a macrocyclic compound of formula (I)